[C-reactive protein in malaria].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Bussière.
Explore the source record for details and available documents.
The determination of possible modifications of pharmacokinetic parameters of carbamazepine by josamycin in an experimental study after chronic administration of the drugs in the rat was undertaken to assay, or not, the enzymatic inhibition hypothesis which is supported in human clinical studies. Our data do not show any alteration in the Cmax, Tmax and AUC parameters of carbamazepine (total and unbound fraction) in case of conjunction with josamycin, but an earlier increase of plasmatic concentrations. The biochemical parameters are not modified, but a significant decrease of total bilirubin compared with controls and carbamazepine alone. The histological study does not show any liver lesion.
The authors report the case of an IgA secreting multiple myeloma which, after a rapid initial remission, relapsed with skin, thyroid, testis and lung metastases without bone recurrence. A review of the medical literature on this subject underlines the poorly differentiated microscopic appearance and the low secretion of paraprotein of these extraosseous plasmacytic tumours which have a poor prognosis due to their increased malignancy.
Levels of alpha 1-acid glycoprotein (alpha 1-AGP) were determined in 40 epileptic patients who had been also treated with carbamazepine (CBZ) and, in some patients, phenobarbital (PB) for at least 3 months. alpha 1-AGP levels were also determined in 28 controls. CBZ dit not alter blood levels of alpha 1-AGP while CBZ-PB decreased them. Such results are at variance with recent studies which suggested an increase of alpha 1-AGP in epileptic patients treated either with phenytoin or phenytoin + PB, or + CBZ, or + primidone.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.